Blog

Transformative study for 1st line Metastatic HER2+ Breast Cancer at ASCO25

Sara Tolaney/X

Jun 4, 2025, 09:58

Transformative study for 1st line Metastatic HER2+ Breast Cancer at ASCO25

Chandler Park, Advisory Dean and Clinical Professor at University of Louisville School of Medicine, shared a post on LinkedIn:

“Congratulations to Dr. Sara Tolaney, Dana-Farber Cancer Institute and the Destiny Breast09 investigators for a Trasnformative study for 1st line metastatic HER2+ breast cancer at ASCO25.

Really enjoyed talking to Dr. Giuseppe Curigliano on the HER2 story that started in Orlando about 20 years ago.”

Chandler Park acknowledged the impact of the DESTINY-Breast09 trial presented at ASCO 2025, recognizing Dr. Sara Tolaney and the investigative team for advancing treatment in first-line metastatic HER2-positive breast cancer.

More posts featuring Chandler Park.

ASCO25 Breast Cancer cancer Chandler Park Dana-Farber Cancer Institute DESTINY-Breast09 fight against cancer Giuseppe Curigliano Global fight against cancer HER2 Metastatic HER2+ Breast Cancer OncoDaily Oncology Orlando Sara Tolaney University of Louisville School of Medicin

MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress

Tabelecleucel (Ebvallo) FDA Update: Approval Delayed Despite Positive Phase 3 Data

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor

"God Invented This" - Pat Soon-Shiong on Cancer Discovery

Yüksel Ürün: Science Is Better When It’s Shared